2010-2017 年哥伦比亚重症监护病房抗生素消耗趋势

Q3 Medicine
Infectio Pub Date : 2024-02-16 DOI:10.22354/24223794.1163
Jorge A. Sánchez-Duque, A. Gaviria-Mendoza, Paula A. Moreno-Gutiérrez, J. F. Gómez-González, Sa Pantoja-Meneses, S. Thahir-Silva, J. Machado-Alba
{"title":"2010-2017 年哥伦比亚重症监护病房抗生素消耗趋势","authors":"Jorge A. Sánchez-Duque, A. Gaviria-Mendoza, Paula A. Moreno-Gutiérrez, J. F. Gómez-González, Sa Pantoja-Meneses, S. Thahir-Silva, J. Machado-Alba","doi":"10.22354/24223794.1163","DOIUrl":null,"url":null,"abstract":"Introduction: Antibiotics are frequently used in intensive care units (ICUs). Objective: To describe the trends of antibiotic use in Colombian ICUs across 8 years. Methods: This was a descriptive study that analyzed the consumption of antibiotics in 11 ICUs in 7 different cities. Data regarding antibiotic consumption during the period 2010 to 2017 were reviewed for patients older than 18 years. Demographic, pharmacological and cost variables were analyzed. Results: A total of 31,886 patients (50.8% men), with a mean age of 60.3±19.8 years, were treated with antibiotics. The most widely used antibiotics were piperacillin-tazobactam (25.2%), ampicillin-sulbactam (21.8%), and vancomycin (21.4%). The use of cefepime increased from 5.7 defined daily doses per 100 bed-days (DBD) in 2010 to 11.3 in 2017, followed by the use of meropenem (14.73 to 20.18 DBD). The average cost per patient/day decreased from USD 16.1 to USD 8.0 (reduction of 50.3%). From the total cost, 41.3% corresponded to meropenem and 25.8% to piperacillin-tazobactam. Conclusions: The antimicrobials used in the ICU correspond to those recommended by the clinical practice guidelines. An increase in the DBD of some cephalosporins, carbapenems and penicillins and a significant reduction in the cost per patient day were observed.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":"571 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in antibiotic consumption in Colombian intensive care units, 2010-2017\",\"authors\":\"Jorge A. Sánchez-Duque, A. Gaviria-Mendoza, Paula A. Moreno-Gutiérrez, J. F. Gómez-González, Sa Pantoja-Meneses, S. Thahir-Silva, J. Machado-Alba\",\"doi\":\"10.22354/24223794.1163\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Antibiotics are frequently used in intensive care units (ICUs). Objective: To describe the trends of antibiotic use in Colombian ICUs across 8 years. Methods: This was a descriptive study that analyzed the consumption of antibiotics in 11 ICUs in 7 different cities. Data regarding antibiotic consumption during the period 2010 to 2017 were reviewed for patients older than 18 years. Demographic, pharmacological and cost variables were analyzed. Results: A total of 31,886 patients (50.8% men), with a mean age of 60.3±19.8 years, were treated with antibiotics. The most widely used antibiotics were piperacillin-tazobactam (25.2%), ampicillin-sulbactam (21.8%), and vancomycin (21.4%). The use of cefepime increased from 5.7 defined daily doses per 100 bed-days (DBD) in 2010 to 11.3 in 2017, followed by the use of meropenem (14.73 to 20.18 DBD). The average cost per patient/day decreased from USD 16.1 to USD 8.0 (reduction of 50.3%). From the total cost, 41.3% corresponded to meropenem and 25.8% to piperacillin-tazobactam. Conclusions: The antimicrobials used in the ICU correspond to those recommended by the clinical practice guidelines. An increase in the DBD of some cephalosporins, carbapenems and penicillins and a significant reduction in the cost per patient day were observed.\",\"PeriodicalId\":38132,\"journal\":{\"name\":\"Infectio\",\"volume\":\"571 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectio\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22354/24223794.1163\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectio","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22354/24223794.1163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

导言:抗生素是重症监护病房(ICU)的常用药物。目的: 描述哥伦比亚重症监护病房 8 年来使用抗生素的趋势:描述哥伦比亚重症监护病房 8 年来使用抗生素的趋势。方法:这是一项描述性研究:这是一项描述性研究,分析了 7 个不同城市 11 个重症监护病房的抗生素使用情况。研究回顾了 2010 年至 2017 年期间 18 岁以上患者的抗生素使用数据。对人口统计学、药理学和成本变量进行了分析。结果如下共有 31886 名患者(50.8% 为男性)接受了抗生素治疗,平均年龄(60.3±19.8)岁。使用最多的抗生素是哌拉西林-他唑巴坦(25.2%)、氨苄西林-舒巴坦(21.8%)和万古霉素(21.4%)。头孢吡肟的使用量从2010年的每100个床日(DBD)5.7个定义日剂量增加到2017年的11.3个,其次是美罗培南的使用量(DBD从14.73个增加到20.18个)。每位患者/天的平均成本从 16.1 美元降至 8.0 美元(降幅为 50.3%)。在总费用中,美罗培南占 41.3%,哌拉西林-他唑巴坦占 25.8%。结论重症监护室使用的抗菌药物符合临床实践指南的建议。一些头孢菌素、碳青霉烯类和青霉素类药物的DBD有所提高,病人每天的费用显著降低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Trends in antibiotic consumption in Colombian intensive care units, 2010-2017
Introduction: Antibiotics are frequently used in intensive care units (ICUs). Objective: To describe the trends of antibiotic use in Colombian ICUs across 8 years. Methods: This was a descriptive study that analyzed the consumption of antibiotics in 11 ICUs in 7 different cities. Data regarding antibiotic consumption during the period 2010 to 2017 were reviewed for patients older than 18 years. Demographic, pharmacological and cost variables were analyzed. Results: A total of 31,886 patients (50.8% men), with a mean age of 60.3±19.8 years, were treated with antibiotics. The most widely used antibiotics were piperacillin-tazobactam (25.2%), ampicillin-sulbactam (21.8%), and vancomycin (21.4%). The use of cefepime increased from 5.7 defined daily doses per 100 bed-days (DBD) in 2010 to 11.3 in 2017, followed by the use of meropenem (14.73 to 20.18 DBD). The average cost per patient/day decreased from USD 16.1 to USD 8.0 (reduction of 50.3%). From the total cost, 41.3% corresponded to meropenem and 25.8% to piperacillin-tazobactam. Conclusions: The antimicrobials used in the ICU correspond to those recommended by the clinical practice guidelines. An increase in the DBD of some cephalosporins, carbapenems and penicillins and a significant reduction in the cost per patient day were observed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infectio
Infectio Medicine-Pharmacology (medical)
CiteScore
1.50
自引率
0.00%
发文量
18
审稿时长
39 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信